The goal of the Nonhuman Primate Support Component is to support the overall program of the CHAVI-ID by performing in vivo passive protection or enhancement studies to characterize the functional activities of mAbs generated by CHAVI-ID investigators, by performing immunization studies with novel immunogens developed by CHAVI investigators, and performing correlative mAb and immune functional studies to use the rhesus monkey as a model to accelerate HlV-1 vaccine development. This work will be facilitated by recent advances we have made in a number of complementing areas, including the development of novel mucosal SIV/SHIV challenge models, novel SHIV constructs expressing transmitted/founder HlV-1 envelopes, adjuvants that substantially increase the immunogenicity of HlV-1 envelope protein immunogens, and recombinant technology for generating monoclonal antibodies from immunized rhesus macaques.
Specific Aims Aim 1. Pursue passive protection studies in rhesus macaques to determine the effectiveness of antibodies with defined specificities and CD8 T cell-produced factors in blocking SHIV/SIV mucosal acquisition.
Aim 2. Perform immunization studies in rhesus macaques to explore novel strategies for vaccine induction of antibodies that might protect against HIV-1 acquisition.
Aim 3. Explore the evolution of broadly neutralizing anti-HIV-1 antibodies in vaccinated rhesus macaques.

Public Health Relevance

Vaccine strategies aimed at preventing mucosal HIV-1 acquisition are needed. The nonhuman primate system an important model system to guide optimal strategies to induce the immune system to make protective immune responses to HIV-1.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Pollara, Justin; Easterhoff, David; Fouda, Genevieve G (2017) Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS 12:216-221
Arakelyan, Anush; Fitzgerald, Wendy; King, Deborah F et al. (2017) Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions. Sci Rep 7:948
Go, Eden P; Ding, Haitao; Zhang, Shijian et al. (2017) Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. J Virol 91:
Verkoczy, Laurent; Alt, Frederick W; Tian, Ming (2017) Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunol Rev 275:89-107
Haynes, Barton F; Mascola, John R (2017) The quest for an antibody-based HIV vaccine. Immunol Rev 275:5-10
Bonsignori, Mattia; Liao, Hua-Xin; Gao, Feng et al. (2017) Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol Rev 275:145-160
Kelsoe, Garnett; Haynes, Barton F (2017) What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. Cold Spring Harb Perspect Biol :
Herschhorn, Alon; Sodroski, Joseph (2017) An entry-competent intermediate state of the HIV-1 envelope glycoproteins. Receptors Clin Investig 4:
Ding, Shilei; Verly, Myriam M; Princiotto, Amy et al. (2017) Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. AIDS Res Hum Retroviruses 33:428-431
Espy, Nicole; Pacheco, Beatriz; Sodroski, Joseph (2017) Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor. Virology 508:90-107

Showing the most recent 10 out of 220 publications